<DOC>
	<DOCNO>NCT00000831</DOCNO>
	<brief_summary>To elucidate relationship virologic risk factor immunologic clinical progression patient receive monotherapy protocol ACTG 175 , compare new treatment regimen combination reverse transcriptase inhibitor long-term recipient monotherapy . Specifically , determine , patient take zidovudine ( AZT ) alone long time , whether beneficial add lamivudine ( 3TC ) AZT switch d4T alone , also determine , patient take didanosine ( ddI ) alone long time , whether beneficial add AZT AZT/3TC ddI . Characteristics virus replication , pathogenicity , resistance think determine durability virologic clinical response nucleoside reverse transcriptase inhibitor . Previous result ACTG 175 suggest either switch ddI addition ddI patient receive AZT result well clinical , virologic , CD4 cell response compare continuation AZT alone .</brief_summary>
	<brief_title>Virologic Responses To New Nucleoside Regimens After Prolonged ZDV ddI Monotherapy</brief_title>
	<detailed_description>Characteristics virus replication , pathogenicity , resistance think determine durability virologic clinical response nucleoside reverse transcriptase inhibitor . Previous result ACTG 175 suggest either switch ddI addition ddI patient receive AZT result well clinical , virologic , CD4 cell response compare continuation AZT alone . Patients prior AZT experience randomize receive either d4T alone AZT/3TC . Patients prior ddI experience randomize receive ddI/AZT ddI/AZT/3TC . PER AMENDMENT 8/27/96 : The study extend 6 month treatment available March 15 , 1997 late . Each patient regularly schedule 12 week safety visit extension period . AS PER AMENDMENT 1/22/97 : The study extend approximately 16 additional week beyond current 6-month extension . Subjects unblinded assigned regimen begin 2/21/97 continue therapy 16 week open-label fashion . AS PER AMENDMENT 5/9/97 : The study extend additional 8 week ; study drug provide 9/15/97 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Recommended : PCP prophylaxis patient CD4 count &lt; = 200 cells/mm3 . Allowed : Chemophylaxis Mycobacterium tuberculosis . Acyclovir . Vaccination pneumococcal vaccine polyvalent . Haemophilus B Conjugate vaccine . Chemoprophylaxis MAC Toxoplasma gondii . Antibiotics . Recombinant erythropoietin ( EPO ) GCSF . Systemic corticosteroid &lt; 21 day . Regularly prescribed medication antipyretic , analgesic , allergy medication , antidepressant , sleep medication , oral contraceptive . Vitamins herbal therapy . Concurrent Treatment : Allowed : Limited local radiation therapy skin . Blood transfusion 3 unit less per 21day period . Acupuncture . Visualization technique . Patients must : Completed AZT ddI monotherapy ACTG 175 remain regimen subsequent interval . Not reach ACTG 175 endpoint prior May 1 , 1995 . Consent parent guardian le 18 year old . PER AMENDMENT 8/27/96 : Patients must study/on treatment time protocol study treatment extend . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Grade 2 bad peripheral neuropathy . Malignancy require systemic therapy . Concurrent Medication : Excluded : AntiHIV drug study drug . Biologic response modifier . Systemic cytotoxic chemotherapy . Any drug know affect glucuronidation and/or clearance AZT . Concurrent Treatment : Excluded : Radiation therapy limit local therapy skin . Patients follow prior condition exclude : History acute chronic pancreatitis . Prior Medication : Excluded : Prior 3TC . Acute therapy infection ( HIV ) medical illness within 14 day prior study entry . Current ethanol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Stavudine</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Drug Combinations</keyword>
</DOC>